Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

by | PRNewswire Asia

–  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study –  The exceptional efficacy of denifanstat (ASC40) observed in the Company’s...

Singapore hosts its first Global Health Film Festival, spotlighting pandemic and planetary health

by | PRNewswire Asia

The two-evening programme on 27-28 January at The Ngee Ann Kongsi Auditorium at the SingHealth Duke-NUS campus convened clinicians, students, policymakers and partners to focus on the importance of outbreak preparedness and planetary health SINGAPORE, Jan. 29,...

Event Offering Great Opportunity to Enjoy Pairing of Japan's Traditional Distilled Spirit "Shochu" and Highest-quality "Miyazaki Wagyu" Beef to Be Held in New York on February 21

by | PRNewswire Asia

-Top "Shochu" Distiller Kirishima Shuzo to Provide Its Signature Distilled Liquor and Japanese Cuisine, including Miyazaki Wagyu "Shabu-shabu"- MIYAKONOJO, Japan, Jan. 29, 2026 /PRNewswire/ — On Saturday, February 21, 2026, in collaboration...

Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

by | PRNewswire Asia

HONG KONG, Jan. 29, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key...

Bupa and Tencent Launch Hong Kong's First Palm-based Check-in Service for Enhanced Healthcare Experiences

by | PRNewswire Asia

AI-powered palm verification set to deliver seamless, contactless and hygienic check-in journeys for patients at Bupa’s healthcare centres HONG KONG, Jan. 29, 2026 /PRNewswire/ — Tencent in collaboration with Bupa Hong Kong ("Bupa"),...

SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

by | PRNewswire Asia

Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine leveraging SKYCovione’s recombinant protein-based platform and nanoparticle technology SK bioscience will continue to strengthen a Mid- to...